Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.

EP: 1.Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

EP: 2.Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)

EP: 3.Case 2: Low-Volume Recurrent mCSPC

EP: 4.Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

Now Viewing

EP: 5.Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Related Videos